Abstract:Recent advances in the development of therapeutic antibodies (Abs) have greatly improved the treatment of otherwise drug-resistant cancers and autoimmune diseases. Antibody activities are mediated by both their Fab and the Fc. However, therapeutic Abs base their protective mechanisms on Fc-mediated effector functions resulting in the activation of innate immune cells by FcRs. Therefore, Fc-bioengineering has been widely used to maximise the efficacy and convenience of therapeutic antibodies. Today, IgG remains the only commercially available therapeutic Abs, at the expense of other isotypes. Indeed, production, sampling, analysis and related in vivo studies are easier to perform with IgG than with IgA due to well-developed tools. However, interest in IgA is growing, despite a shorter serum half-life and a more difficult sampling and purification methods than IgG. Indeed, the paradigm that the effector functions of IgG surpass those of IgA has been experimentally challenged. Firstly, IgA has been shown to bind to its Fc receptor (FcR) on effector cells of innate immunity with greater efficiency than IgG, resulting in more robust IgA-mediated effector functions in vitro and better survival of treated animals. In addition, the two isotypes have been shown to act synergistically. From these results, new therapeutic formats of Abs are currently emerging, in particular chimeric Abs containing two tandemly expressed Fc, one from IgG (Fcγ) and one from IgA (Fcα). By binding both FcγR and FcαR on effector cells, these new chimeras showed improved effector functions in vitro that were translated in vivo. Furthermore, these chimeras retain an IgG-like half-life in the blood, which could improve Ab-based therapies, including in AIDS. This review provides the rationale, based on the biology of IgA and IgG, for the development of Fcγ and Fcα chimeras as therapeutic Abs, offering promising opportunities for HIV-1 infected patients. We will first describe the main features of the IgA- and IgG-specific Fc-mediated signalling pathways and their respective functional differences. We will then summarise the very promising results on Fcγ and Fcα containing chimeras in cancer treatment. Finally, we will discuss the impact of Fcα-Fcγ chimerism in prevention/treatment strategies against infectious diseases such as HIV-1.

Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection

Fc‐FcγR interactions during infections: From neutralizing antibodies to antibody‐dependent enhancement

Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function

Fc-Dependent Immunomodulation Induced by Antiviral Therapeutic Antibodies: New Perspectives for Eliciting Protective Immune Responses

Fcγ Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies

Effective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines

Quantifying the Contribution of Fc-mediated Effector Functions to the Antiviral Activity of Anti-Hiv-1 IgG1 Antibodies in Vivo.

Hierarchical and redundant roles of activating FcγRs in protection against influenza disease by M2e-specific IgG1 and IgG2a antibodies

An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies.

Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody

Intracellular Neutralization Of Viral Infection In Polarized Epithelial Cells By Neonatal Fc Receptor (Fcrn)-Mediated Igg Transport

Prevention of respiratory virus transmission by resident memory CD8+ T cells

Development of functional antibodies against influenza B virus by activation-induced cytidine deaminase in hybridoma cells

Antibody‐mediated control mechanisms of viral infections

Engineered Antibodies to Combat Viral Threats

From Therapeutic Antibodies to Immune Complex Vaccines

Exploiting Pre-Existing CD4<SUP>+</SUP> T Cell Help from Bacille Calmette-Guerin Vaccination to Improve Antiviral Antibody Responses

An Integrated Signaling Threshold Initiates IgG Response toward Virus-like Immunogens

Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functions

Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA

Dendritic Cells Targeting Lactobacillus plantarum Strain NC8 with a Surface-Displayed Single-Chain Variable Fragment of CD11c Induce an Antigen-Specific Protective Cellular Immune Response